Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.

Ängeby, Kristian; Juréen, Pontus; Chryssanthou, Erja; Schön, Thomas

Ängeby, Kristian; Juréen, Pontus; Chryssanthou, Erja; Schön, Thomas.

Afiliação

Ängeby K; Department of Clinical Microbiology MTC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kristian.angeby@karolinska.se.
Juréen P; Department of Preparedness, Swedish Institute for Communicable Disease Control, Solna, Sweden.
Chryssanthou E; Department of Clinical Microbiology MTC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Schön T; Department of Infectious Diseases and Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden.

Int J Mycobacteriol ; 1(4): 177-9, 2012 Dec.

Article em En | MEDLINE | ID: mdl-26785619

Palavras-chave

Antimycobacterial agents; Drug resistance; Drug susceptibility testing; Mycobacteria; Phenothiazines; Wild-type MIC distributions

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int J Mycobacteriol Ano de publicação: 2012 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int J Mycobacteriol Ano de publicação: 2012 Tipo de documento: Article